Neovascular Age Related Macular Degeneration Clinical Trial
Official title:
A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active Comparator Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Chinese Patients With Neovascular Age-Related Macular Degeneration
NCT number | NCT05562947 |
Other study ID # | YR42983 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | June 28, 2024 |
Est. completion date | May 7, 2029 |
This study will evaluate the efficacy, safety, and pharmacokinetics of ranibizumab 100 mg/mL delivered Q24W via the PDS implant compared with ranibizumab 0.5 mg delivered as a Q4W intravitreal injection in Chinese patients with nAMD.
Status | Recruiting |
Enrollment | 68 |
Est. completion date | May 7, 2029 |
Est. primary completion date | February 25, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 50 Years to 80 Years |
Eligibility | Inclusion Criteria: - Initial diagnosis of nAMD within 9 months prior to the screening visit - Previous treatment with at least three anti-VEGF intravitreal injections for nAMD per standard of care within 6 months prior to the screening visit - Demonstrated response to prior anti-VEGF intravitreal treatment since diagnosis - Availability of historical VA data prior to the first anti-VEGF treatment for nAMD up to the screening visit - BCVA of 34 letters or better (20/200 or better approximate Snellen equivalent), using Early Treatment Diabetic Retinopathy Study (ETDRS) chart at a starting distance of 4 meters - All subtypes of nAMD lesions are permissible - Sufficiently clear ocular media and adequate pupillary dilation to allow for analysis and grading by the central reading center of FP, FA, ICGA, FAF, and OCT images Exclusion Criteria: Study Eye - History of vitrectomy surgery, submacular surgery, or other surgical intervention, all for AMD - Prior treatment with Visudyne, external-beam radiation therapy, or transpupillary thermotherapy - Previous treatment with corticosteroid intravitreal injection - Previous intraocular device implantation (not including intraocular lens implants) - Previous laser (any type) used for AMD treatment - Treatment with anti-VEGF agents other than ranibizumab within 1 month prior to the randomization visit - Concurrent conjunctival, Tenon's capsule, and/or scleral condition in the supero temporal quadrant of the eye that may affect the implantation, subsequent tissue coverage, and refill-exchange procedure of the PDS implant - Subretinal hemorrhage that involves the center of the fovea, if the hemorrhage is greater than 0.5 disc area (1.27 mm2) in size at screening - Subfoveal fibrosis or subfoveal atrophy - Retinal pigment epithelial tear - Any concurrent intraocular condition - Active intraocular inflammation (grade trace or above) - History of vitreous hemorrhage - History of rhegmatogenous retinal detachment - History of rhegmatogenous retinal tears or peripheral retinal breaks within 3 months prior to the randomization visit - History of pars plana vitrectomy surgery - Aphakia or absence of the posterior capsule - Spherical equivalent of the refractive error demonstrating more than 8 diopters of myopia - Preoperative refractive error that exceeds 8 diopters of myopia, for patients who have undergone prior refractive or cataract surgery - Intraocular surgery (including cataract surgery) within 3 months preceding the randomization visit - Uncontrolled ocular hypertension or glaucoma - History of glaucoma-filtering surgery, tube shunts, or microinvasive glaucoma surgery - History of corneal transplant Fellow (Non-Study) Eye • Non-functioning fellow eye Either Eye - Prior treatment with brolucizumab (at any time prior to the screening visit) - Prior participation in a clinical trial involving anti-VEGF drugs within 6 months prior to the randomization visit - Choroidal neovascularization due to other causes, such as ocular histoplasmosis, trauma, central serous chorio-retinopathy, or pathologic myopia - Any history of uveitis - Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis |
Country | Name | City | State |
---|---|---|---|
China | Beijing Hospital | Beijing City | |
China | The Second Affiliated Hospital of Harbin Medical University; ophthalmology department | Harbin | |
China | Shanghai First People's Hospital | Shanghai | |
China | Tianjin Medical University Eye Hospital | Tianjin City | |
China | Eye Hospital, Wenzhou Medical University | Wenzhou City |
Lead Sponsor | Collaborator |
---|---|
Hoffmann-La Roche |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in BCVA score averaged over Weeks 36 and 40, as assessed using the ETDRS visual acuity chart at a starting distance of 4 meters | Baseline up to Week 40 | ||
Secondary | Proportion of patients with BCVA score of 38 letters (20/200 approximate Snellen equivalent) or worse averaged over Weeks 36 and 40 | Baseline up to Week 40 | ||
Secondary | Proportion of patients with BCVA score of 38 letters (20/200 approximate Snellen equivalent) or worse averaged over Weeks 44 and 48 | Baseline up to Week 48 | ||
Secondary | Proportion of patients with BCVA score of 69 letters (20/40 approximate Snellen equivalent) or better averaged over Weeks 36 and 40 | Baseline up to Week 40 | ||
Secondary | Proportion of patients with BCVA score of 69 letters (20/40 approximate Snellen equivalent) or better averaged over Weeks 44 and 48 | Baseline up to Week 48 | ||
Secondary | Proportion of patients who gain =0 letters in BCVA score from baseline averaged over Weeks 36 and 40 | Baseline up to Week 40 | ||
Secondary | Proportion of patients who gain = 0 letters in BCVA score from baseline averaged over Weeks 44 and 48 | Baseline up to Week 48 | ||
Secondary | Proportion of patients who lose < 10 or > 5 letters in BCVA score from baseline averaged over Weeks 36 and 40 | Baseline up to Week 40 | ||
Secondary | Proportion of patients who lose < 10 or > 5 letters in BCVA score from baseline averaged over Weeks 44 and 48 | Baseline up to Week 48 | ||
Secondary | Change from baseline in CPT at Week 36 | CPT = center point thickness | Baseline up to Week 36 | |
Secondary | Change from baseline in CST at Week 36 | CST = central subfield thickness | Baseline up to Week 36 | |
Secondary | Change from baseline in CPT at Week 44 | CPT = center point thickness | Baseline up to Week 44 | |
Secondary | Change from baseline in CST at Week 44 | CST = central subfield thickness | Baseline up to Week 44 | |
Secondary | Proportion of patients in the implant arm who do not undergo supplemental treatment with intravitreal ranibizumab 0.5 mg before the first, second, third, fourth, fifth, and sixth fixed refill exchange intervals | Baseline up to 144 weeks | ||
Secondary | Proportion of patients in the implant arm who do not undergo a supplemental treatment that requires subsequent additional supplemental treatments during the study | Baseline up to 144 weeks | ||
Secondary | Proportion of participants with Adverse Events | Baseline up to 144 weeks | ||
Secondary | Incidence and severity of adverse device effects in the PDS patients | Baseline up to 144 weeks | ||
Secondary | Incidence, causality, severity, and duration of anticipated serious adverse device effects in the PDS patients | Baseline up to 144 weeks | ||
Secondary | Observed serum ranibizumab concentrations at specified timepoints | Baseline, Weeks 4, 12, 24, 28, 36, 48 | ||
Secondary | Area under the concentration time curve from 0-24 weeks | Baseline, Weeks 4, 12, 24 | ||
Secondary | Maximum serum concentration of ranibizumab | Baseline, Weeks 4, 12, 24, 28, 36, 48 | ||
Secondary | Minimum serum concentration of ranibizumab | Baseline, Weeks 4, 12, 24, 28, 36, 48 | ||
Secondary | Prevalence of ADAs at baseline and incidence of ADAs during the study | Baseline, Weeks 4, 24, 48 | ||
Secondary | Incidence of treatment-emergent ADAs during the study | Baseline, Weeks 4, 24, 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02251366 -
NVAMD Satellite Study
|
N/A | |
Unknown status |
NCT00767949 -
Safety Study of iSONEP (Sonepcizumab/LT1009) to Treat Neovascular Age-related Macular Degeneration
|
Phase 1 | |
Completed |
NCT00764738 -
Study Investigating OCT, Multifocal ERG, and Microperimetry in Monthly Versus PRN Ranibizumab in Neovascular Age-Related Macular Degeneration
|
Phase 2/Phase 3 | |
Completed |
NCT00383370 -
Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMD
|
Phase 1 | |
Completed |
NCT01678963 -
Efficacy and Safety of Squalamine Lactate Eye Drops in Subjects With Neovascular (Wet) Age-related Macular Degeneration (AMD)
|
Phase 2 | |
Completed |
NCT03930641 -
Study of the Safety of Brolucizumab 6 mg in Prefilled Syringe in Patients With Neovascular Age Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT01863199 -
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
|
Phase 4 | |
Completed |
NCT04239027 -
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
|
Phase 3 | |
Completed |
NCT00574093 -
Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD
|
Phase 2 | |
Completed |
NCT00685100 -
Retinal Effects After Combined Photodynamic Therapy (PDT) With Intravitreal Triamcinolone
|
Phase 3 | |
Completed |
NCT01942213 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.
|
N/A | |
Recruiting |
NCT00640640 -
The Effects of Bevacizumab and Ranibizumab on Ocular Pulse Amplitude in Neovascular Age Related Macular Degeneration (AMD)
|
N/A |